Genpharmasec Limited (BOM:531592)
India · Delayed Price · Currency is INR 1.010
-0.010 (-0.98%)
At close: Aug 21, 2026
Genpharmasec Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,776 | 1,399 | 337.22 | 304.06 | 255.16 | 273.21 |
Other Revenue | 0 | - | - | - | - | - |
| 1,776 | 1,399 | 337.22 | 304.06 | 255.16 | 273.21 | |
Revenue Growth | 337.77% | 314.98% | 10.91% | 19.16% | -6.61% | 28.22% |
Cost of Revenue | 1,642 | 1,286 | 295.48 | 242.33 | 233.97 | 265.65 |
Gross Profit | 133.89 | 113.58 | 41.74 | 61.73 | 21.18 | 7.55 |
Selling, General & Admin | 46.28 | 38.7 | 10.29 | 9.18 | 6.83 | 3.59 |
Other Operating Expenses | 75.2 | 62.65 | 30.81 | 52.09 | 11.67 | 9.18 |
Operating Expenses | 147.25 | 123.04 | 49.21 | 61.69 | 18.7 | 12.91 |
Operating Income | -13.36 | -9.46 | -7.47 | 0.04 | 2.48 | -5.36 |
Interest Expense | -15.17 | -12.4 | -4.34 | -4.09 | -0.56 | - |
Interest & Investment Income | - | - | 2.35 | 0 | 0.31 | 0.65 |
Currency Exchange Gain (Loss) | - | - | 0.96 | 1.83 | 0.55 | 0.16 |
Other Non Operating Income (Expenses) | 28.35 | 31.57 | -0 | -0 | 0.04 | 0.11 |
EBT Excluding Unusual Items | -0.18 | 9.71 | -8.51 | -2.22 | 2.82 | -4.43 |
Gain (Loss) on Sale of Investments | - | - | 27.31 | 4.73 | - | - |
Pretax Income | -0.18 | 9.71 | 18.8 | 2.51 | 2.82 | -4.43 |
Income Tax Expense | 8.11 | 4.11 | 6.49 | 4.2 | -8.43 | -2.34 |
Earnings From Continuing Operations | -8.29 | 5.6 | 12.31 | -1.69 | 11.25 | -2.09 |
Minority Interest in Earnings | 14.77 | 10.43 | - | - | - | - |
Net Income | 6.48 | 16.03 | 12.31 | -1.69 | 11.25 | -2.09 |
Net Income to Common | 6.48 | 16.03 | 12.31 | -1.69 | 11.25 | -2.09 |
Net Income Growth | -70.00% | 30.22% | - | - | - | - |
Shares Outstanding (Basic) | - | 613 | 554 | 307 | 277 | 277 |
Shares Outstanding (Diluted) | - | 613 | 554 | 307 | 277 | 277 |
Shares Change | - | 10.69% | 80.25% | 10.96% | - | 2.06% |
EPS (Basic) | - | 0.03 | 0.02 | -0.01 | 0.04 | -0.01 |
EPS (Diluted) | - | 0.03 | 0.02 | -0.01 | 0.04 | -0.01 |
EPS Growth | - | 30.80% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -180.73 | -27.19 | -29.64 | -30.76 | -24.25 |
Free Cash Flow Per Share | - | -0.29 | -0.05 | -0.10 | -0.11 | -0.09 |
Gross Margin | 7.54% | 8.12% | 12.38% | 20.30% | 8.30% | 2.77% |
Operating Margin | -0.75% | -0.68% | -2.22% | 0.01% | 0.97% | -1.96% |
Profit Margin | 0.36% | 1.15% | 3.65% | -0.56% | 4.41% | -0.77% |
Free Cash Flow Margin | - | -12.91% | -8.06% | -9.75% | -12.05% | -8.88% |
EBITDA | 12.88 | 12.22 | -4.02 | 0.21 | 2.68 | -5.21 |
EBITDA Margin | 0.73% | 0.87% | -1.19% | 0.07% | 1.05% | -1.91% |
D&A For EBITDA | 26.24 | 21.68 | 3.45 | 0.17 | 0.2 | 0.14 |
EBIT | -13.36 | -9.46 | -7.47 | 0.04 | 2.48 | -5.36 |
EBIT Margin | -0.75% | -0.68% | -2.22% | 0.01% | 0.97% | -1.96% |
Effective Tax Rate | - | 42.30% | 34.52% | 167.56% | - | - |
Revenue as Reported | 1,804 | 1,431 | 367.84 | 310.62 | 256.16 | 274.13 |